Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
The Prostate|April 18, 2014
Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancerMasaki Shiota, Akira Yokomizo, Ario Takeuchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 18, 2022
Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancerEiji Kashiwagi, Masaki Shiota, Hidekazu Naganuma, et al.
Oncology Reports|April 8, 2015
Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cellsTakanobu Motoshima, Yoshihiro Komohara, Hasita Horlad, et al.
Urologic Oncology|October 20, 2020
Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitorsAsako Machidori, Masaki Shiota, Satoshi Kobayashi, et al.
Prostate International|August 25, 2018
Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosteroneNaoko Akitake, Masaki Shiota, Hirofumi Obata, et al.
Oncotarget|April 15, 2015
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancerMasaki Shiota, Jennifer L Bishop, Ario Takeuchi, et al.
Prostate International|May 5, 2022
Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancerShigetomo Yamada, Masaki Shiota, Leandro Blas, et al.
Anticancer Research|June 10, 2019
Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate CancerTakeshi Kobayashi, Ryo Namitome, Y U Hirata, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 22, 2021
Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancerMasaki Shiota, Leandro Blas, Satoshi Kobayashi, et al.
Cancer Science|April 19, 2016
Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2Momoe Itsumi, Masaki Shiota, Ario Takeuchi, et al.
Pageof 12